Impax Laboratories — Q3 2015 Earnings Presentation
22 slides from Impax Laboratories's earnings presentation, Nov 9, 2015
Slide 1: Third Quarter 2015 Results
Impax Third Quarter 2015 Results November 9, 2015
Slide 2: Cautionary Statement Regarding Forward Looking Statements
Impax Cautionary Statement Regarding Forward Looking Statements To the extent any statements made inthis news release contain information that is not historical; these statements are forward-looking in nature and express the bees and expectation of maragemert. Such statement are based oy cure expect
Slide 3: Agenda
Agenda
Slide 4: Highlights & Update
Highlights & Update Fred Wilkinson President & Chief Executive Officer
Slide 5: Q3 2015 Highlights
Q3 2015 Highlights + Resolved Warning Letter at Hayward facility » Three generic products approved from facility * Q3 2015 results —- compared to Q3 2014 » Revenue growth of 40% — Growth primarily driven by higher volumes and launches Tower’ acquisition enhanced Brand and Generic portfolio Continued
Slide 6: 1. Focusing on Quality
1. Focusing on Quality Corporate Quality + Enhanced structure and personnel + Resolved Warning Letter in early September 2015 + Three generic approvals since resolution of Warning Letter + GMP certificate issued in September + Continued focus on Quality Improvement Programs and Systems Hayward Middl
Slide 7: 2. Maximizing Generic Platform
2. Maximizing Generic Platform Products Approval 1 Lamotrigine ODT (Lamictal®) - FTF 1015 2 Azelastine Nasal (Astepro®) Re-launch 3 Olopatadine Nasal (Patanase®) AG 4 Oxymorphone IR tablet (Opana®) 4Q14 5 Metaxalone 400mg IR tablet (Skelaxin®)* 1015 6 — Fenofibrate IR tablet (Fenoglide®) AG 7 Cyproh
Slide 8: 2. Maximizing Specialty Pharma Platform
2. Maximizing Specialty Pharma Platform + 12.6% TRx growth prior 4 weeks through 10/30 APY™ + Strong product interest resutts in enhanced physician office access eee. Driving awareness and adoption >80% of commercial and Medicare Part D Rx’s approved by payers Weekly TRx Since Launch 1,906 YZOMIg’ta
Slide 9: 3. Optimizing R&D
3. Optimizing R&D Ss ANDA Pipeline Current U.S. Brand/Generic Market Sales - $19B Pending at FDA - $98 29% Potential/Confirmed Under Development - $108 ‘53% Potential FTF or FTM FTF or FTM 20 I: fa Internal Extemal Internal External Other SOD lControled-Release SOD Aternative Dosage Form + Numient™
Slide 10: 4. Business Development Acceleration
4. Business Development Acceleration + Integration of Tower acquisition complete » Focusing on achieving strategic benefits » Capturing identified synergies of approximately $20 million — $10 million in 2015 and $10 million by end of 2016 * Targeting strategic value-creating opportunities >» Generic
Slide 11: Financial Review
Financial Review Bryan Reasons Senior Vice President & Chief Financial Officer
Slide 12: Q3 2015 Financial Summary
Q3 2015 Financial Summary $ millions, except per share amounts Q3 2015 Eanes 32014 | Change $158.0 Total Revenues $2214 Adjusted Gross Profit sit Adjusted Gross Margin 50.3% Adjusted Research & Development Expense $179 Adjusted Selling, General & Administrative Expense $42.5 Adjusted EBITDA $65.8 Ad
Slide 13: Q3 2015 Generic and Specialty Pharma Summary
Q3 2015 Generic and Specialty Pharma Summary $ millions, except per share amounts Q3 2015 | Q2 2015 Q3 2014 GENERIC DIVISION Total Revenues $180.7 $1747 3.4% $145.6 24.1% Adjusted Gross Profit $773 $752 28% $824 (6.2%) Adjusted Gross Margin 42.8% 43.1% — (0.3)ppts 566% (13.8)ppts Adjusted Operating
Slide 14: Full-year 2015 Financial Guidance Update
Full-year 2015 Financial Guidance Update $ millions Prior | Updated Adjusted Gross Margin Low 50% range Low 50% range Adjusted Research & Development Expense $75 to $80 $75 to $80 Adjusted Selling, General & Administrative Expense $170 to $180 $170 to $180 Adjusted Interest Expense $14 $14 Capital E
Slide 15: Key Priorities
Key Priorities
Slide 16: Slide 16
Slide 17: Appendix
Appendix
Slide 18: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations The following table reconciles reported net income (oss) to adjusted net income (Unaudited, amounts in thousands, except per share and per share data) Three months ended Sept 30, June 20, Sept 30, 2015 2015, 2014 Net income $ 35,755 $ (1,852) $ 15.737 Adjusted to add
Slide 19: Footnotes to Table Reconciling Reported Net Income to Adjusted Net Income
Footnotes to Table Reconciling Reported Net Income to Adjusted Net Income (2) Primarily resulting from the March 2018 acquisition of Tower (including its operating subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC) and Lineage. Included in “Cost of revenues” on the Consolidated Statements o
Slide 20: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations The following table reconciles total Company reported cost of revenues, research and development expenses, and selling, general and administrative expenses to adjusted cost of revenues, adjusted gross profit, adjusted gross margin, adjusted research and development e
Slide 21: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations The following table reconciles reported net income (loss) to adjusted EBITDA. The following table reconciles reported interest expense to adjusted (Unaudited, amounts in thousands) interest expense (Unaudited, amounts in thousands) Three monthsended Three months ende
Slide 22: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations The following tables reconcile the Impax Generics and Impax Specialty Pharma Divisions reported cost of revenues to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted operating income. (Unaudited, amounts in thousands) Generic Divisi